Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
May 2016, Vol 7, No 4
May 2016, Vol 7, No 4
NCCN Panel Examines Impact of the Presidential Election on Cancer Care
By
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
The chances for further policy changes in healthcare over the next several years are expected to be minimal, said panelists during a roundtable discussion at the 2016 National Comprehensive Cancer Network annual conference.
Read Article
Self-Reports of 6-Mercaptopurine Intake in Childhood Acute Lymphoblastic Leukemia Unreliable
By
Phoebe Starr
Hematologic Malignancies
May 2016, Vol 7, No 4
Approximately 40% of children with acute lymphoblastic leukemia (ALL) fail to take 6-mercaptopurine (6-MP) as prescribed, and a sizable majority of parents and children with ALL overreport the intake of a critical drug for maintaining remission, according to a study reported by lead investigator Wendy Landier, PhD, RN, NP, Children’s of Alabama, Birmingham, and colleagues at ASH 2015.
Read Article
Imatinib Can Be Safely Discontinued in Patients with Deep Molecular Response
By
Chase Doyle
Hematologic Malignancies
May 2016, Vol 7, No 4
Long-term follow-up of the French 1 Stop Imatinib Study (STIM1) in patients with chronic myeloid leukemia (CML) has demonstrated that imatinib (Gleevec) can be safely discontinued in patients with a deep molecular response (ie, lasting at least 2 years). According to data presented at ASH 2015, molecular relapse was very rare after 6 months of stopping imatinib, and no relapse was reported after 2 years.
Read Article
Additional Chemotherapy Improves Survival in Women with Residual Disease After Neoadjuvant Chemotherapy
By
Phoebe Starr
Breast Cancer
May 2016, Vol 7, No 4
It is not clear how to treat residual disease after neoadjuvant therapy in patients with early HER2-negative breast cancer. Additional chemotherapy with capecitabine improved survival in this group of patients, according to a large Japanese study presented by lead investigator Masakazu Toi, MD, PhD, Professor, Breast Surgery, Kyoto Hospital, Japan, at the 2015 San Antonio Breast Cancer Symposium.
Read Article
Omit Chemotherapy for Luminal A Breast Cancer?
By
Phoebe Starr
Breast Cancer
May 2016, Vol 7, No 4
Younger patients with luminal A subtype breast cancer may not need chemotherapy, according to a Danish trial presented by lead investigator Torsten O. Nielsen, MD, PhD, Professor, University of British Columbia, Vancouver, Canada, at the 2015 San Antonio Breast Cancer Symposium. Patients with luminal A biological subtype breast cancer have an excellent prognosis, even high-risk patients, the study suggests.
Read Article
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
By
Lisa A. Raedler, PhD, RPh
Drug Updates
May 2016, Vol 7, No 4
On November 16, 2015, the US Food and Drug Administration (FDA) approved the first monoclonal antibody, daratumumab (Darzalex; Janssen Biotech), for the treatment of patients with multiple myeloma who have received at least 3 previous lines of therapy, including a proteasome inhibitor and an IMiD, or for the treatment of patients whose disease is double-refractory to proteasome inhibitors and IMiDs.
Read Article
Cabozantinib Improves on Standard of Care for Second-Line Treatment of Patients with Advanced Renal-Cell Carcinoma
By
Phoebe Starr
Genitourinary Cancers
May 2016, Vol 7, No 4
Cabozantinib (Cabometyx) achieved superior progression-free survival (PFS) versus standard treatment with everolimus in patients with previously treated advanced renal-cell carcinoma in an updated analysis of the phase 3 METEOR trial, the results of which were reported at the 2016 Genitourinary Cancers Symposium.
Read Article
First-in-Class Stem-Cell Inhibitor Active in Pancreatic and Colorectal Cancers
By
Charles Bankhead
GI Cancers
May 2016, Vol 7, No 4
The first-in-class cancer stem-cell inhibitor BBI608 demonstrated activity in advanced pancreatic cancer and colorectal cancer (CRC), according to results of 2 small studies reported at the 2016 Gastrointestinal Cancers Symposium.
Read Article
Decision Aids: Facilitating Communication with Cancer Survivors
By
Chase Doyle
Survivorship
,
Policies & Guidelines
May 2016, Vol 7, No 4
Linking physicians and patients is a major undertaking, but given the ubiquity of smartphone technology and the rise in app development, the healthcare industry is poised to leverage advances in communication and information exchange. At the 2016 Cancer Survivorship Symposium, Steven J. Katz, MD, MPH, Professor of Medicine and Health Management and Policy, University of Michigan, Ann Arbor, discussed the use of deliberation systems to enhance communication with survivors and their care.
Read Article
Multidisciplinary Teamwork Needed for Survivorship Care
By
Chase Doyle
Survivorship
,
Policies & Guidelines
May 2016, Vol 7, No 4
“When we talk about multidisciplinary cancer care teams, I think it is important to discuss MDT [multidisciplinary team] clinical decision-making,” said Dr Jacobs. “How does the team really work together?”
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma